Journal of Hepatology

• 

  Publication Venue For

  • Reply to: "B vitamins for NASH: Use methylcobalamin, not cyanocobalamin"..  78:e35-e36. 2023
  • Reply to: The use of acoustic radiation force-based shear stiffness in non-alcoholic fatty liver disease.  56:996. 2012
  • Reply to "iL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?".  56:742-743. 2012
  • Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.  56:1336-1342. 2012
  • 75 MYOFIBROBLASTS PROVIDE HEDGEHOG PARACRINE SIGNALS THAT DRIVE CHOLANGIOCYTES TO RECRUIT NKT CELLS TO PORTAL TRACTS.  50:S31-S32. 2009
  • The association of family history of liver cancer with hepatocellular carcinoma: a case-control study in the United States..  50:334-341. 2009
  • Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges..  50:184-194. 2009
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients..  49:163-169. 2008
  • Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma..  49:52-60. 2008
  • Fructose consumption as a risk factor for non-alcoholic fatty liver disease..  48:993-999. 2008
  • Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells..  48:98-106. 2008
  • Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia..  47:658-663. 2007
  • Important role of abnormal glycogen structure in the development of liver cirrhosis and progression to hepatocellular carcinoma in patients with glycogen storage disease type-III.  47:300-301. 2007
  • Glycogen storage disease type III-hepatocellular carcinoma a long-term complication?.  46:492-498. 2007
  • Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis..  45:584-591. 2006
  • Interleukin-15 increases hepatic regenerative activity..  45:410-418. 2006
  • Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness..  44:971-983. 2006
  • Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes..  44:842-847. 2006
  • What impact does a specialized center for transplantation and heptobiliary disease have on post-graduate resident training of gastroenterologists and surgeons?.  44:659-662. 2006
  • Who should perform liver transplantation? Should that be the transplant surgeon, the hepatobilary surgeon, or the general surgeon? Part I: the transplant surgeon..  44:647-649. 2006
  • The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice..  44:411-421. 2006
  • A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients..  44:88-96. 2006
  • Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease..  43:1060-1066. 2005
  • Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma..  43:854-862. 2005
  • Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice..  43:317-323. 2005
  • Treatment of acute hepatitis C infection: more pieces of the puzzle?.  42:293-296. 2005
  • Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients..  41:935-942. 2004
  • The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients..  40:484-490. 2004
  • Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics..  38:681-687. 2003
  • Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C..  37:848-854. 2002
  • The role of endogenous heme oxygenase in the initiation of liver injury following limb ischemia/reperfusion..  36:624-630. 2002
  • Prognostic significance of glutamine synthetase expression in unifocal advanced hepatocellular carcinoma..  33:247-253. 2000
  • Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver..  26:1266-1273. 1997
  • Non-parenchymal cell responses in paracetamol (acetaminophen)-induced liver injury..  20:537-541. 1994
  • Impact of resmetirom-mediated reductions in liver volume and steatosis compared with placebo on the quantification of fibrosis using second harmonic generation in a serial liver biopsy study 2022
  • LIVRQNac increases fatty acid oxidization in a primary human hepatocyte model of non-alcoholic steatohepatitis 2022
  • Aldafermin reduces hydrophobic bile acids in a 24-week, randomized, double-blind, placebo-controlled, multicenter study in patients with non-alcoholic steatohepatitis 2021
  • Atherosclerotic cardiovascular risk assessment in a 24-week, randomized, double-blind, placebo-controlled study of aldafermin 2021
  • Reduction in Fibrosis and Steatohepatitis Imaging and Biomarkers in a Phase 3 52 Week Resmetirom NASH Trial 2021
  • MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study 2020
  • Magnetic resonance imaging-proton density fat fraction (MRIPDFF) to predict treatment response on NASH liver biopsy: a secondary analysis of the resmetirom randomized placebo-controlled phase 2 clinical trial 2020
  • Non-invasive tests of fibrosis and risk of liver-related complications: observations following successful sofosbuvir-based treatment in patients with HCV cirrhosis 2020
  • Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis 2020
  • Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies 2019
  • MRI-PDFF response in MGL-3196 and placebo treated patients predicts reduction in ballooning and inflammation components of NAS and NASH resolution in a 36-week serial liver biopsy study 2019
  • PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects 2019
  • Early and late liver-related mortality following drug induced liver injury from amoxicillin-clavulanate 2018
  • JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study 2018
  • MGL-3196, a selective thyroid hormone receptor-beta agonist significantly decreases hepatic fat in NASH patients at 12 weeks, the primary endpoint in a 36 week serial liver biopsy study 2018
  • NGM282 improves fibrosis and NASH-related histology in 12 weeks in patients with biopsy-confirmed NASH, which is preceded by significant decreases in hepatic steatosis, liver transaminases and fibrosis markers at 6 weeks 2018
  • Skeletal muscle index indicates mortality risk more accurately than psoas muscle index in patients with cirrhosis. From the FLEXIT consortium. 2018
  • NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients 2017
  • Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis 2016
  • Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study 2016
  • Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis 2016
  • INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION 2016
  • Osteopontin Promotes Cholangiocyte Chemokine Secretion and Macrophage Accumulation in Murine Liver Fibrosis 2016
  • PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis 2016
  • Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study 2016
  • CROSS-TALK BETWEEN IL13 AND HEDGEHOG PATHWAYS CONTRIBUTES TO SCHISTOSOMIASIS MANSONI FIBROSIS 2015
  • P0469 : Markers of tissue repair and cellular aging are increased in liver tissue of patients with dual chronic HIV/HCV infections 2015
  • P0826 : Effectiveness of simeprevir (SMV)-containing regimens among patients with chronic hepatitis C virus (HCV) in various us practice settings: Interim analysis of the sonet study 2015
  • P0935 : Non-alcoholic steatohepatitis (NASH): 2 complementary dietary mouse models 2015
  • P1131 : Autoimmune hepatitis-like drug induced liver injury 2015
  • P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study 2015
  • P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS 2014
  • P612 OSTEOPONTIN NEUTRALIZATION ABROGATES THE LIVER PROGENITOR CELL RESPONSE AND FIBROGENIC OUTCOMES IN MICE 2014
  • 242 HYPONATREMIA IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: INTERIM DATA FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL HYPONATREMIA REGISTRY 2013
  • 312 PRAZOSIN AN ALPHA1 ADRENOCEPTOR ANTAGONIST PROTECTS LIVER FROM ACETAMINOPHEN INDUCED ACUTE LIVER INJURY AND EXPANDS THE PROGENITOR CELL POPULATION 2013
  • 1364 DIAGNOSING HEPATOTOXICITY ATTRIBUTABLE TO HERBAL & DIETARY SUPPLEMENTS (HDS): TEST-RETEST RELIABILITY OF A NOVEL CAUSALITY ASSESSMENT TOOL 2012
  • 331 ACUTE LIVER FAILURE IN MICE FOLLOWING DELETION OF CFLIP - A KEY ROLE OF APOPTOSIS SIGNALING PATHWAYS IN TISSUE HOMEOSTASIS 2012
  • 376 STATINS INDUCE SENESCENCE OF ACTIVATED HSC BY INHIBITION OF THE HEDGEHOG PATHWAY 2012
  • 379 THREE PHENOTYPICALLY AND FUNCTIONALLY DISTINCT MONOCYTE SUBSETS AND THEIR ROLE IN HUMAN LIVER FIBROSIS 2012
  • 681 HYPONATREMIA IN HOSPITALIZED PATIENTS WITH CIRRHOSIS: INTERIM DATA FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL HYPONATREMIA REGISTRY INDICATES THAT HYPONATREMIA IS FREQUENTLY NOT TREATED 2012
  • 884 EXPLORATION OF SERUM ADIPOCYTOKINE ASSOCIATIONS WITH IL28B GENOTYPE IN CHRONIC HEPATITIS C 2012
  • 1334 DYSREGULATION OF HOST INNATE IMMUNITY IN HCV GENOTYPE 1 INFECTED IL28B CT/TT HAPLOTYPE PATIENTS WITH DEPRESSED VIRAL KINETICS AND THERAPEUTIC RESPONSE 2011
  • 144 SYNERGISTIC ROLES OF HEPATIC ENCEPHALOPATHY AND OBSTRUCTIVE SLEEP APNEA IN DISTURBANCE OF SLEEP ARCHITECTURE IN PATIENTS WITH CIRRHOSIS 2011
  • 674 HEPATOCYTE-SPECIFIC DELETION OF CFLIP ENHANCES LIVER INJURY FROM STREPTOZOTOCIN-INDUCED HYPERGLYCEMIA INVOLVING ACTIVATION OF JNK 2011
  • 869 COFFEE CONSUMPTION INCREASES HEPATIC EXPRESSION OF CYTOCHROME P450S AND SIGNIFICANTLY REDUCES LIVER FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 2011
  • DELETION OF CFLIP IN HEPATOCYTES AUGMENTS CCL4-INDUCED LIVER INJURY INVOLVING ACTIVATION OF MITOGEN ACTIVATED PROTEIN KINASES 2011
  • 1179 INTERFERON LAMBDA GENOTYPE AND LOW SERUM LDL CHOLESTEROL LEVELS IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION 2010
  • 307 HIGH PREVALENCE OF PRE-EXISTING ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEPATITIS C (HCV) PATIENTS WHICH IS NOT ASSOCIATED WITH IMPAIRED RESPONSE TO PEG-INTERFERON 2010
  • 69 THE CASPASE-8 HOMOLOGUE FLIP MODULATES HEPATOCARCINOGENESIS IN MICE 2010
  • 46 ABLATION OF C-FLIP AUGMENTS CD95- AND GALACTOSAMINE/LPS-INDUCED LIVER INJURY THROUGH ACTIVATION OF C-JUN N-TERMINAL KINASE (JNK) 2008
  • 482 ACETYLCHOLINE INDUCES FIBROGENIC EFFECTS IN HUMAN PRIMARY HEPATIC STELLATE CELLS 2008